Icon Plc (ICLR) 73.15 $ICLR
ICON (ICLR) Set to Acquire Clinical Research Management
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:34AM CDT
ICON Plc (ICLR) recently announced plans to acquire Clinical Research Management Inc. for an undisclosed sum.
EVHC: 26.00 (+0.30), BEAT: 17.50 (+0.96), AHS: 43.14 (+0.46), ICLR: 73.15 (+0.40)
ICON to Acquire Clinical Research Management, Inc.
BusinessWire - Thu Jun 30, 7:00AM CDT
ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain customary closing conditions (including applicable regulatory approvals), to acquire Clinical Research Management, Inc. (ClinicalRM). The acquisition will enhance ICON's ability to access the market for government sponsored research and further enhances ICON's capabilities in the areas of Vaccines and Infectious Disease.
ICLR: 73.15 (+0.40)
SmarTrend Watching for Potential Pullback in Shares of ICON After 2.83% Gain
Comtex SmarTrend(R) - Wed Jun 22, 2:18PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $65.14 to a high of $67.47. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $65.88 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ICLR: 73.15 (+0.40)
ICON and Pfizer Extend Ties, Sign New Agreement
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:12AM CDT
ICON Plc (ICLR), recently signed a three-year service agreement with its existing customer Pfizer Inc. (PFE).
AIRM: 38.33 (+0.51), PFE: 36.15 (+0.03), AHS: 43.14 (+0.46), ICLR: 73.15 (+0.40)
New Research from ICON Demonstrates Support for 'Bring Your Own Device' Approach in Clinical Trials
BusinessWire - Wed Jun 15, 2:00AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced research showing many pharmaceutical and clinical research organisations (CROs) support the use of a 'Bring Your Own Device' (BYOD) approach in clinical studies, enabling patients to use their own mobile devices to collect patient-reported outcomes (PRO) data. The research highlights how commonly-cited concerns around the use of patients' own devices are not as much of a deterrent to adoption as is often thought.
ICLR: 73.15 (+0.40)
ICON Announces Service Agreement with Pfizer
BusinessWire - Fri Jun 10, 5:00AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE
FE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed.
PFE: 36.15 (+0.03), ICLR: 73.15 (+0.40)
Downgrade Alert for ICON (ICLR)
Comtex SmarTrend(R) - Thu Jun 09, 3:20AM CDT
ICON (NASDAQ:ICLR) was downgraded from Market Perform to Underperform at Avondale today. The stock closed yesterday at $69.90 on volume of 407,000 shares, below average daily volume of 447,000. There is potential upside of 14.8% for shares of ICON based on a current price of $69.90 and an average consensus analyst price target of $80.22. The stock should find initial resistance at its 50-day moving average (MA) of $71.69 and further resistance at its 200-day MA of $72.54.
ICLR: 73.15 (+0.40)
ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards
BusinessWire - Mon May 16, 4:55AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, together with Pfizer, it has won the Clinical Research Team of the Year award at the inaugural Clinical and Research Excellence (CARE) Awards which took place in Boston on the 27th April.
ICLR: 73.15 (+0.40)
ICON Set to Possibly Rebound After Yesterday's Selloff of 8.53%
Comtex SmarTrend(R) - Tue Apr 26, 3:47PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $66.39 to a high of $72.06. Yesterday, the shares fell 8.5%, which took the trading range below the 3-day low of $71.27 on volume of 706,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ICLR: 73.15 (+0.40)
Icon PLC beats 1Q profit forecasts
Automated Insights - Tue Apr 26, 5:06AM CDT
DUBLIN 18, Ireland (AP) _ Icon PLC (ICLR) on Tuesday reported first-quarter net income of $63 million.
ICLR: 73.15 (+0.40)
ICON Reports First Quarter 2016 Results
BusinessWire - Tue Apr 26, 5:00AM CDT
--Backlog of business up 9% year on year to $3.95 billion
ICLR: 73.15 (+0.40)
Mr. Thomas Lynch Notifies ICON of His Retirement as Chairman and That He Will Not Stand for Re-Election to the Board of Directors at the Annual General Meeting
BusinessWire - Tue Mar 29, 5:00AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Thomas Lynch, non-executive chairman of the board of directors, has notified ICON that he will retire as chairman on 31 March 2016 and will not stand for re-election to the board at the company's annual general meeting in July 2016. Mr. Lynch has been a non-executive director of ICON since 1994 and served as senior independent director from 2010 to 2012 and as chairman since January 2013.
ICLR: 73.15 (+0.40)
4 Hot Stocks to Keep an Eye Out For in Medical Services
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 8:15AM CDT
A gradual transformation from providing volume to value-based-care model is underway, which is expected to bring in a revolutionary change in the healthcare service system.
PRXL: 66.16 (-0.04), PRAH: 42.97 (+0.45), ICLR: 73.15 (+0.40), CGIX: 2.00 (unch)
Envision Healthcare (EVHC) Set to Buy EPMG in Michigan
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 10:10AM CDT
Envision Healthcare Holdings Inc. (EVHC) is set to acquire Michigan-based Emergency Physicians Medical Group (EPMG) for approximately $120 million.
PRXL: 66.16 (-0.04), EVHC: 26.00 (+0.30), PRAH: 42.97 (+0.45), ICLR: 73.15 (+0.40)
ICON and ICHOM to Roll out GLOBE Benchmarking Program
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 10:20AM CST
ICON Public Limited Company (ICLR) recently announced that its data management, data analytics and consultancy capabilities have been selected by the International Consortium for Health Outcomes Measurement.
ABMD: 115.94 (+1.79), LMNX: 21.72 (+0.06), CRY: 12.19 (-0.04), ICLR: 73.15 (+0.40)
ICON Selected by the International Consortium for Health Outcomes Measurement to Help Advance Value-based Healthcare
BusinessWire - Tue Mar 08, 5:00AM CST
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by the International Consortium for Health Outcomes Measurement (ICHOM) to advance value-based healthcare through the launch of a global healthcare outcomes benchmarking program called GLOBE. ICON is using its data management, data analytics and consultancy expertise to enable ICHOM to provide healthcare providers with a secure platform to share and compare high-quality, risk-adjusted health outcomes - the results of care that matter most to patients - that will lead to improvements in healthcare.
ICLR: 73.15 (+0.40)
Varicose Veins Global Clinical Trials Review, H1, 2015 - Analysis, Technologies & Forecast Report - Key Vendors: BTG Plc, EMS SA, ICON Plc - Research and Markets
BusinessWire - Thu Mar 03, 6:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltw526/varicose_veins) has announced the addition of the "Varicose Veins Global Clinical Trials Review, H1, 2015" report to their offering.
ICLR: 73.15 (+0.40)
ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases
BusinessWire - Tue Feb 09, 4:00AM CST
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as data management partner for the 100,000 Genomes Project.
ICLR: 73.15 (+0.40)
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
Zacks Equity Research - Zacks Investment Research - Wed Jan 13, 8:30AM CST
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
ANW: 6.14 (+0.24), HZNP: 19.12 (+0.41), TNP: 4.99 (+0.08), ICLR: 73.15 (+0.40), DAC: 4.28 (+0.24)
5 Smart PIIGS Stocks to Buy Now
Swarup Gupta - Zacks Investment Research - Tue Jan 12, 1:18PM CST
While stocks from Ireland offer a strong economic environment, picks from Greece are available at attractive valuations.
ANW: 6.14 (+0.24), HZNP: 19.12 (+0.41), TNP: 4.99 (+0.08), ICLR: 73.15 (+0.40), DAC: 4.28 (+0.24)
ICON (ICLR) Set to Acquire Clinical Research Management
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:34AM CDT
ICON Plc (ICLR) recently announced plans to acquire Clinical Research Management Inc. for an undisclosed sum.
EVHC: 26.00 (+0.30), BEAT: 17.50 (+0.96), AHS: 43.14 (+0.46), ICLR: 73.15 (+0.40)
ICON to Acquire Clinical Research Management, Inc.
BusinessWire - Thu Jun 30, 7:00AM CDT
ICON plc, (NASDAQ:ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has agreed, subject to certain customary closing conditions (including applicable regulatory approvals), to acquire Clinical Research Management, Inc. (ClinicalRM). The acquisition will enhance ICON's ability to access the market for government sponsored research and further enhances ICON's capabilities in the areas of Vaccines and Infectious Disease.
ICLR: 73.15 (+0.40)
SmarTrend Watching for Potential Pullback in Shares of ICON After 2.83% Gain
Comtex SmarTrend(R) - Wed Jun 22, 2:18PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $65.14 to a high of $67.47. Yesterday, the shares gained 2.8%, which took the trading range above the 3-day high of $65.88 on volume of 339,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ICLR: 73.15 (+0.40)
ICON and Pfizer Extend Ties, Sign New Agreement
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:12AM CDT
ICON Plc (ICLR), recently signed a three-year service agreement with its existing customer Pfizer Inc. (PFE).
AIRM: 38.33 (+0.51), PFE: 36.15 (+0.03), AHS: 43.14 (+0.46), ICLR: 73.15 (+0.40)
New Research from ICON Demonstrates Support for 'Bring Your Own Device' Approach in Clinical Trials
BusinessWire - Wed Jun 15, 2:00AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced research showing many pharmaceutical and clinical research organisations (CROs) support the use of a 'Bring Your Own Device' (BYOD) approach in clinical studies, enabling patients to use their own mobile devices to collect patient-reported outcomes (PRO) data. The research highlights how commonly-cited concerns around the use of patients' own devices are not as much of a deterrent to adoption as is often thought.
ICLR: 73.15 (+0.40)
ICON Announces Service Agreement with Pfizer
BusinessWire - Fri Jun 10, 5:00AM CDT
ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced it has signed a three-year agreement with Pfizer Inc. (NYSE
FE). Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed. PFE: 36.15 (+0.03), ICLR: 73.15 (+0.40)
Downgrade Alert for ICON (ICLR)
Comtex SmarTrend(R) - Thu Jun 09, 3:20AM CDT
ICON (NASDAQ:ICLR) was downgraded from Market Perform to Underperform at Avondale today. The stock closed yesterday at $69.90 on volume of 407,000 shares, below average daily volume of 447,000. There is potential upside of 14.8% for shares of ICON based on a current price of $69.90 and an average consensus analyst price target of $80.22. The stock should find initial resistance at its 50-day moving average (MA) of $71.69 and further resistance at its 200-day MA of $72.54.
ICLR: 73.15 (+0.40)
ICON and Pfizer Honoured as Clinical Research Team of the Year at the Clinical and Research Excellence Awards
BusinessWire - Mon May 16, 4:55AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that, together with Pfizer, it has won the Clinical Research Team of the Year award at the inaugural Clinical and Research Excellence (CARE) Awards which took place in Boston on the 27th April.
ICLR: 73.15 (+0.40)
ICON Set to Possibly Rebound After Yesterday's Selloff of 8.53%
Comtex SmarTrend(R) - Tue Apr 26, 3:47PM CDT
ICON (NASDAQ:ICLR) traded in a range yesterday that spanned from a low of $66.39 to a high of $72.06. Yesterday, the shares fell 8.5%, which took the trading range below the 3-day low of $71.27 on volume of 706,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ICLR: 73.15 (+0.40)
Icon PLC beats 1Q profit forecasts
Automated Insights - Tue Apr 26, 5:06AM CDT
DUBLIN 18, Ireland (AP) _ Icon PLC (ICLR) on Tuesday reported first-quarter net income of $63 million.
ICLR: 73.15 (+0.40)
ICON Reports First Quarter 2016 Results
BusinessWire - Tue Apr 26, 5:00AM CDT
--Backlog of business up 9% year on year to $3.95 billion
ICLR: 73.15 (+0.40)
Mr. Thomas Lynch Notifies ICON of His Retirement as Chairman and That He Will Not Stand for Re-Election to the Board of Directors at the Annual General Meeting
BusinessWire - Tue Mar 29, 5:00AM CDT
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Thomas Lynch, non-executive chairman of the board of directors, has notified ICON that he will retire as chairman on 31 March 2016 and will not stand for re-election to the board at the company's annual general meeting in July 2016. Mr. Lynch has been a non-executive director of ICON since 1994 and served as senior independent director from 2010 to 2012 and as chairman since January 2013.
ICLR: 73.15 (+0.40)
4 Hot Stocks to Keep an Eye Out For in Medical Services
Zacks Equity Research - Zacks Investment Research - Tue Mar 22, 8:15AM CDT
A gradual transformation from providing volume to value-based-care model is underway, which is expected to bring in a revolutionary change in the healthcare service system.
PRXL: 66.16 (-0.04), PRAH: 42.97 (+0.45), ICLR: 73.15 (+0.40), CGIX: 2.00 (unch)
Envision Healthcare (EVHC) Set to Buy EPMG in Michigan
Zacks Equity Research - Zacks Investment Research - Fri Mar 18, 10:10AM CDT
Envision Healthcare Holdings Inc. (EVHC) is set to acquire Michigan-based Emergency Physicians Medical Group (EPMG) for approximately $120 million.
PRXL: 66.16 (-0.04), EVHC: 26.00 (+0.30), PRAH: 42.97 (+0.45), ICLR: 73.15 (+0.40)
ICON and ICHOM to Roll out GLOBE Benchmarking Program
Zacks Equity Research - Zacks Investment Research - Thu Mar 10, 10:20AM CST
ICON Public Limited Company (ICLR) recently announced that its data management, data analytics and consultancy capabilities have been selected by the International Consortium for Health Outcomes Measurement.
ABMD: 115.94 (+1.79), LMNX: 21.72 (+0.06), CRY: 12.19 (-0.04), ICLR: 73.15 (+0.40)
ICON Selected by the International Consortium for Health Outcomes Measurement to Help Advance Value-based Healthcare
BusinessWire - Tue Mar 08, 5:00AM CST
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by the International Consortium for Health Outcomes Measurement (ICHOM) to advance value-based healthcare through the launch of a global healthcare outcomes benchmarking program called GLOBE. ICON is using its data management, data analytics and consultancy expertise to enable ICHOM to provide healthcare providers with a secure platform to share and compare high-quality, risk-adjusted health outcomes - the results of care that matter most to patients - that will lead to improvements in healthcare.
ICLR: 73.15 (+0.40)
Varicose Veins Global Clinical Trials Review, H1, 2015 - Analysis, Technologies & Forecast Report - Key Vendors: BTG Plc, EMS SA, ICON Plc - Research and Markets
BusinessWire - Thu Mar 03, 6:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltw526/varicose_veins) has announced the addition of the "Varicose Veins Global Clinical Trials Review, H1, 2015" report to their offering.
ICLR: 73.15 (+0.40)
ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases
BusinessWire - Tue Feb 09, 4:00AM CST
ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been selected by Genomics England as data management partner for the 100,000 Genomes Project.
ICLR: 73.15 (+0.40)
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
Zacks Equity Research - Zacks Investment Research - Wed Jan 13, 8:30AM CST
The Zacks Analyst Blog Highlights: Aegean Marine Petroleum Network, Danaos, Tsakos Energy Navigation, Horizon Pharma and ICON Public Limited
ANW: 6.14 (+0.24), HZNP: 19.12 (+0.41), TNP: 4.99 (+0.08), ICLR: 73.15 (+0.40), DAC: 4.28 (+0.24)
5 Smart PIIGS Stocks to Buy Now
Swarup Gupta - Zacks Investment Research - Tue Jan 12, 1:18PM CST
While stocks from Ireland offer a strong economic environment, picks from Greece are available at attractive valuations.
ANW: 6.14 (+0.24), HZNP: 19.12 (+0.41), TNP: 4.99 (+0.08), ICLR: 73.15 (+0.40), DAC: 4.28 (+0.24)
